Metformin suppresses NFE2L1 pathway activation to inhibit gap junction beta protein expression in NSCLC.
Shuo YuHui RenTingting LiuXiaoyan HanHui GuoQian NingYang LiHong ZhouMingwei ChenTinghua HuPublished in: Cancer medicine (2024)
This emphasizes the potential of targeting GJBs as a viable treatment approach for NSCLC patients receiving metformin.